Primary:
- To investigate the efficacy of insulin glargine (in terms of change in A1c from baseline
to endpoint A1c < 7%)
Secondary:
- To investigate the safety of insulin glargine (in terms of hypoglycaemia, including
symptomatic, non-symptomatic and nocturnal hypoglycaemia)
- To investigate whether beta cell function is preserved if this therapy is initiated
before 2nd OAD (oral anti-diabetic drug) failure